CoChat

Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study

Open access
Chen, Kang, Chen, Li, Shan, Zhongyan, Wang, Guixia, Qu, Shen, Qin, Guijun, Yu, Xuefeng, Xin, Weiquan, Hsieh, Tsung‐han, Mu, Yiming · 2024 · Diabetes, Obesity and Metabolism
Cited by 35

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aim: To investigate the efficacy and safety of beinaglutide as an adjunct to lifestyle intervention among non‐diabetic Chinese individuals with overweight or obesity. Methods: This multicentre, randomized, double‐blind, placebo‐controlled trial (ChiCTR1900023428) included 427 Chinese adults with a body mass index of 28 kg/m 2 or higher (obesity) or 24‐27.9 kg/m 2 (overweight) with weight‐related complications. Patients were randomized in a 2:1 ratio to receive 0.2 mg of beinaglutide (subcutaneous) thrice daily or placebo for 16 weeks. Co‐primary endpoints were body weight change and the proportion of patients with a weight reduction of 5% or more. Results: Mean body weight change from baseline to week 16 was −6.0% and −2.4% in the beinaglutide ( n = 282) and placebo ( n = 138) groups, respectively; the mixed model repeated measures difference was −3.6% (95% confidence interval: −4.6% to −2.6%; P < .0001). At week 16, more beinaglutide‐treated patients achieved a weight reduction of 5% or more (58.2% vs. 25.4% [placebo], odds ratio: 4.4; P < .0001) and of 10% or more (21.3% vs. 5.1% [placebo], odds ratio: 5.5; P < .0001). Beinaglutide also resulted in greater waist circumference reduction (difference: −1.81 cm; P < .01). The weight regain rate 12 weeks after beinaglutide treatment was 0.78%. Nausea (transient and mild‐to‐moderate) was the most common adverse event in the beinaglutide group (49.3% vs. 7.1% [placebo]). More patients receiving beinaglutide discontinued treatment because of adverse events (5.9% vs. 0.7% [placebo]). Pancreatitis or an increased resting heart rate was not observed in the beinaglutide group. Conclusion: Beinaglutide combined with lifestyle intervention resulted in significant and clinically meaningful weight reduction with good tolerance in non‐diabetic Chinese individuals with overweight or obesity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.15360

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 14

  1. 10.1155/2022/5476454 · DOI
  2. 10.1056/NEJMoa1614362 · DOI · Paper page
  3. 10.1016/S2213-8587(21)00045-0 · DOI · Paper page
  4. 10.1038/s41467-018-05383-2 · DOI · Paper page
  5. 10.1016/j.isci.2022.104809 · DOI
  6. 10.1016/j.lfs.2020.118966 · DOI · Paper page
  7. 10.1002/dmrr.3158 · DOI · Paper page
  8. Wang G, 2021, Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity arch, Endocrinol Metab, 65, 421
  9. Zhou BF, 2002, Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut‐off points of body mass index and waist circumference in Chinese adults, Biomed Environ Sci, 15, 83
  10. 10.2337/dc20-S008 · DOI · Paper page
  11. 10.1161/JAHA.113.000668 · DOI · Paper page
  12. 10.1016/j.atherosclerosis.2011.06.033 · DOI
  13. 10.1186/s12916-022-02273-9 · doi:10.1186/s12916-022-02273-9
  14. 10.1038/nrcardio.2016.84 · DOI

Cited by

Metadata

Authors
Chen, K., Chen, L., Shan, Z., Wang, G., Qu, S., Qin, G., Yu, X., Xin, W., Hsieh, T., & Mu, Y.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2023-11-09
Volume
26
Issue
2
Pages
690-698
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W4388550897
Cited by
35
References
9
FWCI
4.48
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.